ReviewDrug design, development and therapy2026
Weight-Scaled Dose Optimization of Intravenous Anesthetics in Patients with Obesity: General Anesthesia and Procedural Sedation.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity alters the pharmacokinetics and pharmacodynamics of intravenous anesthetics, complicating weight-based dose selection. This narrative review examines weight-scaling strategies and effective-dose estimates (ED50/ED95) for propofol, ciprofol, and remimazolam in patients with obesity undergoing general anesthesia or procedural sedation. Targeted searches of PubMed/MEDLINE were supplemented by DOI and title searches in Europe PMC and publisher records. Evidence was selected purposively according to clinical relevance, study design, population, dosing phase, and outcome, prioritizing obesity-specific studies. General pharmacological evidence was considered separately to contextualize findings and evidence gaps. The evidence supporting dose optimization is broader for propofol than for ciprofol or remimazolam. Propofol studies support weight-informed initial dosing followed by individualized adjustment, although no single weight scalar is appropriate across all settings. Obesity-specific induction and dose-finding studies of ciprofol and remimazolam provide preliminary information, but limited study numbers and population diversity restrict generalizability. Their maintenance dosing in patients with obesity remains insufficiently characterized. ED50/ED95 values reflect responses under specific study conditions and should not be interpreted as routine clinical dosing recommendations. For procedural sedation, dose selection requires consideration of the intended sedation depth, concomitant medications, and respiratory risk. Weight-based calculations provide initial dose estimates, while titration guided by clinical response and appropriate pharmacodynamic monitoring remains essential. The proposed dosing framework distinguishes approaches supported by broader clinical evidence from preliminary findings and suggestions based on pharmacological reasoning. The latter require further validation before routine adoption. Adequately powered, multicenter comparative trials should address maintenance dosing, extreme obesity, and clinically meaningful safety and recovery outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.